Researchers have identified two sugar-binding proteins that impede the viral entry of circulating SARS-CoV-2 variants. The team, spearheaded by researchers at IMBA—Institute of Molecular Biotechnology of the Austrian Academy of Sciences—may have found the "Achilles' heel" of the virus, with potential for pan-variant therapeutic interventions. The findings are now published in the EMBO Journal.